WallStSmart

Alcon AG (ALC)vsMilestone Scientific (MLSS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 115183% more annual revenue ($10.86B vs $9.42M). ALC leads profitability with a 5.9% profit margin vs -44.0%. ALC earns a higher WallStSmart Score of 51/100 (C-).

ALC

Buy

51

out of 100

Grade: C-

Growth: 4.7Profit: 4.5Value: 3.3Quality: 6.8
Piotroski: 3/9

MLSS

Avoid

21

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 5.5
Piotroski: 2/9Altman Z: -24.40
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-22.0%)

Margin of Safety

-22.0%

Fair Value

$65.08

Current Price

$66.03

$0.95 premium

UndervaluedFair: $65.08Overvalued
MLSSUndervalued (+72.8%)

Margin of Safety

+72.8%

Fair Value

$0.98

Current Price

$0.44

$0.54 discount

UndervaluedFair: $0.98Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

MLSS2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
22.3%8/10

Revenue surging 22.3% year-over-year

Areas to Watch

ALC4 concerns · Avg: 2.8/10
Return on EquityProfitability
3.8%3/10

ROE of 3.8% — below average capital efficiency

Profit MarginProfitability
5.9%3/10

5.9% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
53.8x2/10

Premium valuation, high expectations priced in

MLSS4 concerns · Avg: 3.5/10
Price/BookValuation
11.1x4/10

Trading at 11.1x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$41.61M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Price/Book, Debt/Equity. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bull Case : MLSS

The strongest argument for MLSS centers on Debt/Equity, Revenue Growth. Revenue growth of 22.3% demonstrates continued momentum.

Bear Case : ALC

The primary concerns for ALC are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 53.8x leaves little room for execution misses.

Bear Case : MLSS

The primary concerns for MLSS are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

ALC profiles as a value stock while MLSS is a growth play — different risk/reward profiles.

MLSS carries more volatility with a beta of 1.05 — expect wider price swings.

MLSS is growing revenue faster at 22.3% — sustainability is the question.

ALC generates stronger free cash flow (414M), providing more financial flexibility.

Bottom Line

ALC scores higher overall (51/100 vs 21/100). MLSS offers better value entry with a 72.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Milestone Scientific

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Milestone Scientific, Inc. develops computer-controlled anesthetic delivery devices for the medical and dental markets in the United States, China, and internationally. The company is headquartered in Livingston, New Jersey.

Visit Website →

Want to dig deeper into these stocks?